The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice

Simple item page

Simple item page

Full item details

creativework.keywords - en
Fc-effector
convalescent plasma
ADCC
COVID-19
neutrophils
macrophages
SARS-CoV-2
IgG
IgM
IgA
dc.contributor.author
Ullah, Irfan
Beaudoin-Bussières, Guillaume
Symmes, Kelly
Cloutier, Marc
Ducas, Eric
Tauzin, Alexandra
Laumaea, Annemarie
Grunst, Michael W.
Dionne, Katrina
Richard, Jonathan
Bégin, Philippe
Mothes, Walther
Kumar, Priti
Bazin, Renée
Finzi, Andrés
Uchil, Pradeep D.
dc.date.accepted
2022-12-14
dc.date.accessioned
2024-01-12T14:44:54Z
dc.date.available
2024-01-12T14:44:54Z
dc.date.issued
2022-12-29
dc.date.submitted
2022-06-15
dc.description.abstract - en
HIGHLIGHTS •COVID-19 convalescent plasma (CCP) therapy with robust Fc function can protect mice •Fc activity of CCPs can serve as secondary defense when neutralization is compromised •Fc functions facilitate cross-reactive immunity against SARS-CoV-2 variants of concern •Fc functions can serve as one of the key profiles when selecting CCPs for therapy SUMMARY COVID-19 convalescent plasmas (CCPs) are chosen for plasma therapy based on neutralizing titers and anti-Spike immunoglobulin levels. However, CCP characteristics that promote SARS-CoV-2 control are complex and incompletely defined. Using an in vivo imaging approach, we demonstrate that CCPs with low neutralizing (ID50 ≤ 1:250), but moderate to high Fc-effector activity, in contrast to those with poor Fc function, delay mortality and/or improve survival of SARS-CoV-2-challenged K18-hACE2 mice. The impact of innate immune cells on CCP efficacy depended on their residual neutralizing activity. Fractionation of a selected CCP revealed that IgG and Ig(M + A) were required during therapy, but the IgG fraction alone sufficed during prophylaxis. Finally, despite reduced neutralization, ancestral SARS-CoV-2-elicited CCPs significantly delayed Delta and Beta-induced mortality suggesting that Fc-effector functions contribute to immunity against VOCs. Thus, Fc activity of CCPs provide a second line of defense when neutralization is compromised and can serve as an important criterion for CCP selection.
dc.identifier.citation
Ullah I, Beaudoin-Bussières G, Symmes K, et al. The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice. Cell Reports Medicine. 2023;4(1). doi:https://doi.org/10.1016/j.xcrm.2022.100893
dc.identifier.doi
https://doi.org/10.1016/j.xcrm.2022.100893
dc.identifier.uri
https://open-science.canada.ca/handle/123456789/1747
dc.language.iso
en
dc.publisher
Cell Press
dc.relation.isversionof
https://open-science.canada.ca/handle/123456789/1744
dc.rights - en
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
dc.rights - fr
Creative Commons Attribution - Pas d'utilisation commerciale - Pas de modification 4.0 International (CC BY-NC-ND 4.0)
dc.rights.openaccesslevel - en
Gold
dc.rights.openaccesslevel - fr
Or
dc.rights.uri - en
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.uri - fr
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.fr
dc.subject - en
Health
dc.subject - fr
Santé
dc.subject.en - en
Health
dc.subject.fr - fr
Santé
dc.title - en
The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice
dc.type - en
Article
dc.type - fr
Article
local.acceptedmanuscript.articlenum
100893
local.article.journalissue
1
local.article.journaltitle
Cell Reports Medicine
local.article.journalvolume
4
local.peerreview - en
Yes
local.peerreview - fr
Oui
Download(s)

Original bundle

Now showing 1 - 1 of 1

Thumbnail image

Name: ullah-fc-effector-function-covid-19-convalescent-plasma-treatment-efficacy-mice.pdf

Size: 16.93 MB

Format: PDF

Download file

Page details

Date modified: